ELF5A-2 Antibody

What is eIF5A-2 and how does it differ from the more common eIF5A-1?

eIF5A-2 is an isoform of the eukaryotic translation initiation factor 5A with 84% sequence identity to the ubiquitous eIF5A-1. While eIF5A-1 is expressed in most cell types, eIF5A-2 expression is normally limited to human testis and brain tissues. The isoforms show notable structural differences, including lack of immunological cross-reactivity and different binding affinities to deoxyhypusine synthase (DHS). Their Km values as substrates for DHS differ significantly (1.5 ± 0.2 μM for eIF5A-1 versus 8.3 ± 1.4 μM for eIF5A-2), indicating different enzymatic interactions .

What is the hypusine modification and why is it important for eIF5A-2 function?

Both eIF5A isoforms undergo a unique post-translational modification to form hypusine [Nε-(4-amino-2-hydroxybutyl)lysine]. This modification is essential for eIF5A function and sustained cell proliferation. eIF5A is the only known cellular protein to contain this modification, making it a unique regulatory element in translation. The hypusine modification occurs through a two-step process involving deoxyhypusine synthase and deoxyhypusine hydroxylase, and is critical for the protein's role in translation elongation .

How can I detect eIF5A-2 in my research samples?

Detection of eIF5A-2 requires careful selection of methods and controls due to its similarity to eIF5A-1. Western blotting using specific antibodies is the most common approach, with antibodies that predominantly recognize eIF5A-2 over eIF5A-1. When performing Western blot analysis, researchers should expect a band at approximately 18 kDa. For immunohistochemistry, both frozen and paraffin-embedded sections can be used with appropriate antibodies. RT-PCR and Northern blotting can detect eIF5A-2 at the transcript level, with Northern blotting revealing multiple eIF5A-2 mRNA forms due to alternative polyadenylation sites .

What controls should I include when studying eIF5A-2 expression?

When studying eIF5A-2, several controls are essential:

• Positive controls: Include cell lines known to express eIF5A-2, such as UACC-1598 (ovarian cancer) or SW-480 (colorectal adenocarcinoma).

• Negative controls: Use cell lines with minimal eIF5A-2 expression as negative controls.

• Comparison with eIF5A-1: Parallel detection of eIF5A-1 can serve as an internal control and provide context for relative expression levels.

• Loading controls: Standard loading controls should be included to ensure equal sample loading.

• Antibody validation: Include controls to demonstrate antibody specificity, particularly important given the potential for cross-reactivity between eIF5A isoforms .

How can I distinguish between eIF5A-1 and eIF5A-2 in my experiments?

Distinguishing between these highly similar proteins requires careful experimental design:

• Specific antibodies: Use antibodies raised against unique epitopes, particularly from the C-terminal domain where sequence divergence is greater.

• mRNA analysis: Design primers that target divergent regions for RT-PCR analysis.

• Expression patterns: Compare expression across tissues where differential expression is expected (eIF5A-2 is normally limited to testis and brain).

• Molecular techniques: Northern blot analysis can distinguish multiple eIF5A-2 mRNA species (ranging from approximately 1.5 kb to 5.5 kb) resulting from alternative polyadenylation sites at positions 638, 1483, 3627, and 5534 from the 5′-terminal .

What is the role of eIF5A-2 in cancer development and progression?

eIF5A-2 has been implicated in cancer development through several mechanisms:

• The EIF5A2 gene has been suggested as a candidate oncogene associated with ovarian cancers, which frequently display amplification of chromosome 3q26 where the gene is located.

• Overexpression of eIF5A-2 has been detected in multiple cancer types, most notably ovarian and colorectal cancers.

• As eIF5A-2 is involved in translation regulation, its abnormal expression may alter the cellular proteome, potentially affecting the production of proteins involved in proliferation, invasion, or metastasis.

• The contrast between limited expression in normal tissues and overexpression in cancer suggests eIF5A-2 may contribute to malignant transformation .

How does eIF5A-2 function at the molecular level in translation regulation?

eIF5A-2 functions as a translation factor that particularly affects specific subsets of proteins rather than global translation. While initially classified as an initiation factor, eIF5A proteins (including eIF5A-2) are now recognized to play crucial roles in translation elongation. The hypusine modification is essential for this function. In CD8+ T cells, eIF5A has been shown to facilitate translation of specific subsets of proteins that regulate proliferation and effector functions, particularly IFNγ production. This suggests eIF5A-2 may similarly regulate translation of specific mRNAs in a context-dependent manner .

What protein-protein interactions have been identified for eIF5A-2?

Key protein interactions for eIF5A-2 include:

• Deoxyhypusine synthase (DHS): eIF5A-2 forms complexes with DHS that differ from those formed by eIF5A-1, with different binding kinetics (Km value of 8.3 ± 1.4 μM versus 1.5 ± 0.2 μM for eIF5A-1).

• Translation machinery: As a translation factor, eIF5A-2 interacts with ribosomes and other components of the translation apparatus.

• In Arabidopsis, eIF5A-2 has been shown to interact with cytokinin signaling components, including CYTOKININ RESPONSE1 (CRE1) and ARABIDOPSIS PHOSPHOTRANSFER PROTEIN (AHP) proteins, suggesting potential roles beyond direct translation functions .

What are the challenges in generating specific antibodies against eIF5A-2?

Generating specific antibodies against eIF5A-2 presents several challenges:

• High sequence similarity (84%) with eIF5A-1 limits unique epitope availability.

• Post-translational hypusine modification may affect antibody recognition.

• Low expression levels in most normal tissues complicate validation against endogenous proteins.

Researchers should target the most divergent regions (particularly in the C-terminal domain) and perform extensive validation using positive controls (e.g., UACC-1598 cells) and negative controls. Available antibodies show some degree of specificity, but weak cross-reactivity with eIF5A-1 may still be observed .

What immunohistochemistry protocols work best for eIF5A-2 detection in tissue sections?

Based on available protocols for eIF5A detection:

• Both immersion-fixed frozen sections and paraffin-embedded sections can be used.

• Antibody concentrations should be optimized: approximately 5 μg/mL for frozen sections and 1.7 μg/mL for paraffin-embedded sections.

• HRP-conjugated detection systems with DAB chromogen and hematoxylin counterstain provide good visualization.

• In normal tissues, eIF5A shows cytoplasmic localization, particularly visible in hepatocytes in human liver samples and in the developing central nervous system in embryonic tissues.

• When working specifically with eIF5A-2, researchers should include appropriate positive controls such as testis, brain, or cancer tissues with known overexpression .

How should multiple eIF5A-2 mRNA bands be interpreted in Northern blot analysis?

The multiple bands observed in Northern blot analysis of eIF5A-2 mRNA are the result of alternative polyadenylation:

• The EIF5A2 gene contains multiple polyadenylation signals (AATAAA) at positions 588, 1460, 3608, and 5511 bases from the 5′-terminal of the 5′-UTR.

• This results in multiple mRNA species after polyadenylation at sites 638 (A), 1483 (B), 3627 (C), and 5534 (D).

• All these mRNA forms are poly(A) RNAs as confirmed by oligo-dT purification.

• The different mRNA species encode the same protein but may differ in stability, localization, or translation efficiency.

Researchers should be aware of this complexity when designing Northern blot experiments and interpreting results, as the pattern of bands may vary depending on cell type or experimental conditions .

How is eIF5A-2 involved in immune function and inflammation?

Recent research has uncovered important roles for eIF5A in immune function. In CD8+ T cells, eIF5A function is regulated dynamically upon activation through post-translational modification. It facilitates translation of specific protein subsets that regulate proliferation and key effector functions, particularly IFNγ production, TNF production, and cytotoxicity. eIF5A is essential for long-term survival of effector CD8+ T cells. While these studies focused on eIF5A-1, the functional similarity between the isoforms suggests eIF5A-2 may play similar roles in specific contexts, potentially contributing to post-transcriptional regulation important for coordinating immune responses .